Skip to main content
Fig. 5 | Allergy, Asthma & Clinical Immunology

Fig. 5

From: Expression of COX-1, COX-2, 5-LOX and \(\hbox {CysLT}_2\) in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease

Fig. 5

\(\hbox {CysLT}_2\) immunoreactivity (IRS). Results of the staining of nasal (ac) and bronchial (df) samples for \(\hbox {CysLT}_2\) are shown as boxplot diagrams. The lower and upper boundaries indicate the 25% and 75% quartile, respectively. Minimum and maximum values are indicated as whiskers and the dot represents the group median. Outliers were plotted as individual points. a Nasal respiratory epithelium (AIA: \(n=19\), ATA: \(n=14\), NPwA: \(n=14\)), b nasal submucosal glands (AIA: \(n=15\), ATA: \(n=15\), NPwA: \(n=12\)) and c nasal squamous epithelium (AIA: \(n=15\), ATA: \(n=14\), NPwA: \(n=14\)), without significant differences in patient group comparisons. d Bronchial respiratory epithelium (AIA: \(n=13\), ATA: \(n=8\), NPwA: \(n=5\)), e bronchial submucosal glands (AIA: \(n=7\), ATA: \(n=6\), NPwA: \(n=4\)) and f bronchial squamous epithelium (AIA: \(n=5\), ATA: \(n=1\), NPwA: \(n=3\)), without significant differences in patient group comparisons

Back to article page